In summary, our study identified peripheral IgM+ memory B cells with high PD-1 and PD-L1 expressions as an alternative potential indicator to predict the responses to anti-PD-1 monotherapy in Chinese advanced NSCLC. This evidence concerns the gene CD40LG and non-small cell lung carcinoma.